Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study
| Autor: | Scott Fung, Bettina E. Hansen, Mina S. Farag, Harry L.A. Janssen, Carla S. Coffin, Mayur Brahmania, Sarah Haylock-Jacobs, Alexander Wong, Philip Wong, Giada Sebastiani, Edward Tam, Alnoor Ramji, Brian Conway, Curtis Cooper, Keith Tsoi, Karen Doucette |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Canada Renal function Kidney Tenofovir alafenamide Gastroenterology 03 medical and health sciences 0302 clinical medicine Hepatitis B Chronic Chronic hepatitis Fumarates Virology Internal medicine medicine Humans In patient 030212 general & internal medicine Adverse effect Tenofovir Alanine Hepatology business.industry Hepatitis B medicine.disease Infectious Diseases Cohort 030211 gastroenterology & hepatology business Kidney disease |
| Zdroj: | Journal of viral hepatitisREFERENCES. 28(6) |
| ISSN: | 1365-2893 |
| Popis: | Tenofovir alafenamide fumarate (TAF) has high plasma stability resulting in fewer renal adverse events compared to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) patients. We aimed to study the effectiveness and renal safety of TAF in a real-world setting, in patients with or without compromised kidney function. CHB patients (Nucleos(t)ide Analogue [NA]-naive or experienced) who received TAF >1 year from 11 academic institutions as part of the Canadian Hepatitis B Network (CanHepB) were included. Kidney function was measured by estimated glomerular filtration rate (eGFR) as per Cockcroft-Gault. Patients were followed for up to 160 weeks. Of 176 patients receiving TAF, 143 switched from NA (88% TDF), and 33(19%) were NA naive. Majority of NA-naive patients (75%) achieved undetectable HBV DNA after one year of TAF treatment. Majority of patients with eGFR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|